Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Denali Therapeutics Inc.

Denali Therapeutics is dedicated to defeating neurodegenerative diseases by breaking through historical barriers in scientific research and clinical development in order to deliver safe and effective medicines to patients and families.  Our scientific approach is based on three core principles: rigorous assessment of genetic targets, engineering brain delivery, and using biomarkers to guide development.

Our team thrives in a work environment that is scientifically driven, impact-focused, supportive, and collaborative. Our ability to have a positive impact on people’s lives is directly related to the trust we have in each other and our ability to unify our diverse backgrounds and experience behind our purpose to defeat degeneration.

Biomatics Capital Partners

Alaska Permanent Fund

ARCH Venture Partners

Flagship Pioneering

Baillie Gifford

F-Prime Capital

Eight Roads Ventures

Denali Therapeutics

The #bloodbrainbarrier protects the brain from toxins, but also prevents medicines from entering the brain. We’ve invented a Transport Vehicle (TV) designed to enable protein-based medicines to be carried across that barrier and delivered throughout the brain via existing biological pathways. This novel brain delivery technology has the potential to address a variety of diseases that cause damage inside the brain, potentially making further medical advancements possible. 
#DefeatDegeneration #BrainAwarenessWeek 

We reported our Q3 financial results and business highlights. Read our press release: https://lnkd.in/gubA5Ck2

#TeamDenali joined the Alzheimer's Association of Northern California & Northern Nevada for the Walk to End Alzheimer's in San Francisco this past weekend. Together with the local community, we've taken steps to increase awareness and support research. Thank you to all who participated in this inspiring annual event!   #Walk2EndAlz #AlzheimersAwareness 
#defeatdegeneration

Over the weekend, Denali team members participated in Project Alive's inaugural Hunter syndrome Family Fair, enjoying a day filled with education, connection and Halloween-themed activities with more than 30 MPS II families from across the country! We extend our gratitude to Project Alive for inviting Denali to be a part of this event and value the opportunity to connect with the community and partake in the festive trick-or-treating fun. 

Our team was delighted to participate in the 37th Annual Family and Scientific Conference organized by the National MPS Society in Bethesda, MD. It was another impactful gathering, uniting a diverse community dedicated to having a positive impact in the lives of individuals with MPS and their families. We are grateful for the collaboration and the chance to highlight Denali's research contributions and efforts to develop potential new treatments in MPS. #MPSFamily2023 #defeatdegeneration 

	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
asset turnover				0.20 -	0.05 75.28%	0.21 333.88%	0.03 83.44%	0.07 114.33%	0.29 285.64%
cash conversion cycle									-203.96 -
cash per share	10.22 -	27.76 171.46%	27.15 2.20%	5.01 81.53%	4.34 13.34%	13.49 210.44%	7.12 47.20%	10.64 49.48%	7.53 29.25%
company equity multiplier	-2.35 -	1.07 145.39%	1.04 1.89%	1.21 15.85%	1.40 15.73%	1.39 0.47%	1.46 4.65%	1.40 4.00%	1.12 20.10%
days of inventory outstanding
days of payables outstanding									206.94 -
days of sales outstanding				24.15 -		6.17 -	9.20 49.05%		2.98 -
dividend yield
ebit per revenue				-0.36 -	-7.99 2,125.74%	0.19 102.34%	-6.08 3,352.75%	-3.14 48.31%	-0.60 81.06%
ebt per ebit	1.01 -	0.99 1.54%	0.98 1.29%	0.78 20.12%	0.93 18.82%	1.15 23.55%	0.98 14.20%	0.96 2.83%	0.74 22.84%
effective tax rate			0.03 -	-0.28 899.96%	0.00 100.63%	0.01 545.05%	0.00 82.73%	-0.00 103.26%	-0.00 220.72%
enterprise value multiple	-2.04 -	-1.14 44.09%	-0.17 84.75%	-39.60 22,689.33%	-7.76 80.40%	138.47 1,883.79%	-17.53 112.66%	-10.09 42.45%	-15.96 58.22%
fixed asset turnover				5.13 -	0.33 93.56%	4.57 1,281.34%	0.70 84.70%	1.46 108.19%	4.61 217.02%
free cash flow per share	-6.03 -	-12.22 102.77%	-5.31 56.51%	0.50 109.49%	-1.77 451.44%	3.79 313.81%	-1.81 147.74%	-2.09 15.59%	-2.70 29.10%
gross profit margin				1 -	1 0%	1 0%	1 0%	1 0%	0.95 5.06%
interest coverage			-46.11 -		-14.01 -			-23.06 -
inventory turnover
long term debt to capitalization					0.15 -	0.05 64.42%	0.06 8.57%	0.05 15.60%	0.04 13.64%
net income per ebt	1 -	1 0%	1 0%	1 0%	1.00 0.18%	0.99 0.97%	1.00 0.96%	1.00 0.20%	1.00 0.01%
net profit margin				-0.28 -	-7.41 2,540.00%	0.21 102.86%	-5.97 2,917.70%	-3.01 49.67%	-0.44 85.38%
operating cash flow per share	-5.01 -	-11.26 124.95%	-5.12 54.53%	0.54 110.57%	-1.59 393.00%	3.82 340.88%	-1.74 145.55%	-1.95 12.07%	-2.61 33.68%
operating cycle									2.98 -
operating profit margin				-0.36 -	-7.99 2,125.74%	0.19 102.34%	-6.08 3,352.75%	-3.14 48.31%	-0.60 81.06%
payables turnover									1.76 -
pretax profit margin				-0.28 -	-7.42 2,544.69%	0.21 102.89%	-5.98 2,890.99%	-3.01 49.77%	-0.44 85.38%
price fair value	-4.12 -	0.54 113.13%	0.50 7.20%	3.50 596.45%	4.22 20.53%	7.93 88.10%	5.63 29.00%	3.35 40.54%	2.86 14.62%
receivables turnover				15.11 -		59.16 -	39.69 32.91%		122.42 -
return on assets	-0.46 -	-0.32 30.15%	-0.18 43.32%	-0.05 69.78%	-0.36 552.48%	0.04 112.41%	-0.21 566.70%	-0.22 7.88%	-0.13 43.63%
return on capital employed	-0.50 -	-0.33 33.56%	-0.19 42.85%	-0.07 61.36%	-0.42 469.53%	0.04 109.75%	-0.29 804.44%	-0.31 7.81%	-0.18 41.18%
return on equity	1.07 -	-0.34 131.71%	-0.19 44.39%	-0.07 65.00%	-0.50 655.12%	0.06 112.36%	-0.30 588.39%	-0.31 3.56%	-0.14 54.96%
total debt to capitalization				0.03 -	0.16 360.06%	0.06 63.60%	0.06 10.43%	0.05 12.25%	0.05 11.87%

COM:DENALITHERAPEUTICS

Denali Therapeutics Inc

Last Close

24.42

21/11 21:00

Market Cap

3.09B

Beta: -

Volume Today

1.46M

Avg: -

Preview